Last updated: August 8, 2026
Casodex, the brand name for bicalutamide, has moved from a high-value prostate-cancer product to a largely generic market. AstraZeneca’s commercial position weakened after US patent and regulatory exclusivity ended, while newer androgen-receptor pathway therapies displaced bicalutamide in advanced disease. Current revenue exposure is concentrated in low-cost generic bicalutamide, non-US markets, and residual clinical use rather than branded Casodex sales.
What is Casodex and how is bicalutamide used?
Casodex is an oral nonsteroidal antiandrogen. Bicalutamide blocks androgen receptors and is used with a luteinizing hormone-releasing hormone, or LHRH, agonist for metastatic prostate cancer. The US product was marketed primarily as 50 mg tablets.
The FDA-approved US indication is treatment of Stage D2 metastatic prostate carcinoma in combination with an LHRH analog. Bicalutamide does not suppress testosterone production by itself. It blocks androgen signaling at the receptor level, which differentiates it from surgical castration, LHRH agonists, LHRH antagonists, and androgen-synthesis inhibitors such as abiraterone.
| Attribute |
Casodex |
| Active ingredient |
Bicalutamide |
| Drug class |
Nonsteroidal androgen-receptor antagonist |
| Original developer |
Imperial Chemical Industries, later associated with AstraZeneca |
| US brand holder |
AstraZeneca |
| FDA approval |
1995 |
| Principal US strength |
50 mg |
| Main indication |
Metastatic prostate cancer with an LHRH analog |
| Administration |
Oral, once daily |
| Current competitive position |
Generic and largely mature |
| Biosimilar exposure |
None; bicalutamide is a small molecule |
The FDA label also identifies a 150 mg dose used in other jurisdictions. The 150 mg monotherapy presentation did not obtain the same US commercial role as the 50 mg combination regimen. [1]
How did Casodex generate revenue during its growth phase?
Casodex benefited from three commercial factors: oral administration, broad use in prostate-cancer androgen deprivation, and limited competition from newer androgen-receptor pathway agents during the 1990s and early 2000s.
AstraZeneca’s annual reports placed Casodex among the company’s major growth products during the period before generic erosion. Peak annual global sales were approximately $1 billion, depending on the reporting year and currency basis. The product generated substantial sales in the United States, Europe, Japan, and other markets where bicalutamide was used with medical castration. [2][3]
Historical revenue drivers
Casodex revenue expanded through:
- Increasing diagnosis and treatment of prostate cancer.
- Use alongside LHRH agonists in metastatic disease.
- Long treatment duration in patients receiving androgen deprivation.
- International adoption of bicalutamide 50 mg and 150 mg regimens.
- Limited early competition from modern androgen-receptor inhibitors.
The product’s economics were stronger when AstraZeneca controlled branded pricing. Once generic bicalutamide entered, the market shifted rapidly toward price competition and pharmacy substitution.
When did Casodex lose exclusivity?
Casodex lost its primary US small-molecule patent protection in the 2000s, with generic competition following after the relevant patent and regulatory barriers expired. Generic bicalutamide became commercially available in the United States during the late 2000s and early 2010s.
The foundational bicalutamide patent family included US Patent No. 4,636,505, which covered chemical compounds in the relevant antiandrogen class. The patent’s original term was insufficient to preserve branded exclusivity into the 2010s under the modern 20-year-from-filing system. Later patent and regulatory protections did not create a durable second product life for Casodex. [4]
| Exclusivity event |
Commercial effect |
| 1995 US approval |
Initiated branded market protection |
| Early 2000s patent expiry period |
Opened the path to generic entry |
| Late 2000s generic approvals |
Created rapid price and volume substitution |
| 2010s |
Branded Casodex became commercially marginal |
| 2020s |
Bicalutamide is a mature generic active ingredient |
The relevant commercial conclusion is that Casodex has no meaningful current US exclusivity barrier comparable with a live compound patent, a protected formulation, or a still-active regulatory exclusivity period.
What patents protect Casodex and bicalutamide?
The historical Casodex estate was primarily a compound and use patent estate rather than a complex delivery-platform estate.
Compound patents
The foundational patent position covered bicalutamide-related antiandrogen compounds. US Patent No. 4,636,505 is the principal historical US patent associated with the compound family. Related foreign patents supported protection in Europe, Japan, and other major pharmaceutical markets.
Compound patents were commercially important because they covered the active pharmaceutical ingredient itself. Once those rights expired, manufacturers could generally enter with tablets containing bicalutamide without reproducing AstraZeneca’s brand, packaging, or clinical data package.
Formulation patents
Casodex did not develop a durable commercial moat from an extended-release formulation, transdermal system, injectable formulation, or complex delivery technology. The product is an immediate-release oral tablet with a relatively straightforward generic-development pathway.
This matters for erosion risk. Products protected by difficult formulations, device components, or specialized manufacturing processes can retain branded share after compound-patent expiry. Casodex had fewer such barriers.
Method-of-use patents
The therapeutic use of androgen-receptor blockade in prostate cancer was part of the product’s historical value, but method-of-use protection did not prevent broad generic substitution after the active ingredient became available. Generic manufacturers could market bicalutamide for approved indications through the abbreviated new drug application pathway, subject to applicable labeling and patent certifications.
Casodex therefore lacked the layered patent structure seen in some newer oncology products, where compound, crystalline form, dosing, combination, biomarker, and method-of-use patents extend commercial protection.
What is the Orange Book status of Casodex?
Casodex’s current Orange Book relevance is limited because the product’s principal exclusivity period has ended and generic bicalutamide products are approved. The Orange Book historically identified the listed patents and expiration information supporting the branded product’s approval. [5]
The commercial implications are:
- Generic manufacturers can rely on the reference product’s safety and efficacy findings through the ANDA pathway.
- Bicalutamide tablets are subject to therapeutic substitution and pharmacy-level price competition.
- Any remaining brand listing does not restore the former monopoly.
- The value of historical patent challenges has largely been realized through generic market access.
Which companies challenged Casodex patents?
Generic-drug companies, including major US and international manufacturers, pursued bicalutamide approvals as patent and regulatory barriers expired. The relevant competitor set included firms active in oral oncology generics, such as Teva, Mylan, Sandoz, Dr. Reddy’s Laboratories, and other regional manufacturers.
Publicly significant current Paragraph IV litigation is not a central market issue for Casodex. The principal competitive event was the transition from AstraZeneca’s branded product to multiple approved generic suppliers.
How did Paragraph IV filings affect Casodex?
A Paragraph IV certification allows an ANDA applicant to state that a listed patent is invalid, unenforceable, or not infringed. For Casodex, any such challenge would have accelerated the timing of generic competition if the applicant prevailed or settled for an agreed launch date.
The economic effect of a successful Paragraph IV challenge would have been substantial because:
- Bicalutamide tablets are relatively simple to manufacture.
- Multiple suppliers could enter after the first generic launch.
- The product had no major device or delivery barrier.
- Clinical differentiation among suppliers was limited.
- Prices typically decline sharply as additional generic manufacturers enter.
The 180-day first-filer exclusivity mechanism could temporarily concentrate generic economics, but that advantage would diminish as additional approvals entered the market.
How strong is the Casodex patent estate?
The current patent estate is weak from a commercial protection perspective. Historically, the estate was adequate to support a large branded franchise, but it did not retain meaningful defensive value after compound protection ended.
| Patent-estate factor |
Assessment |
| Active compound protection |
Expired |
| Immediate-release tablet protection |
Limited |
| Extended-release technology |
Not a major Casodex defense |
| Device dependence |
None |
| Manufacturing complexity |
Low to moderate |
| Method-of-use durability |
Limited after generic approval |
| Biosimilar barrier |
Not applicable |
| Current generic vulnerability |
High |
The estate’s historical strength came from timing and clinical adoption, not from a diversified portfolio of long-lived secondary patents.
What generic entry risks exist for Casodex?
Generic entry risk is effectively realized in the United States and other mature markets. The remaining risks are commercial rather than binary patent risks.
Price erosion
Bicalutamide is a conventional oral generic. As supplier count increases, average selling prices tend to fall. The brand can retain limited demand from prescribers or patients who prefer the branded product, but reimbursement policies usually favor generic substitution.
Volume migration
Volume shifted from AstraZeneca to generic suppliers after approval of ANDA products. Prescribers also moved toward newer therapies with stronger evidence in metastatic castration-resistant and metastatic hormone-sensitive prostate cancer.
Therapeutic substitution
Bicalutamide competes with:
- Abiraterone plus prednisone.
- Enzalutamide.
- Apalutamide.
- Darolutamide.
- LHRH agonists and antagonists.
- Surgical castration.
- Other antiandrogens in selected treatment settings.
The newer agents generally command higher prices because they have broader modern treatment positioning, stronger clinical differentiation, or use in earlier disease states.
How does Casodex compare with newer prostate-cancer drugs?
Casodex remains inexpensive and familiar, but it is strategically weaker than newer androgen-receptor pathway inhibitors.
| Product |
Active ingredient |
Commercial position |
Patent and exclusivity profile |
| Casodex |
Bicalutamide |
Mature generic; low price |
Principal protection expired |
| Zytiga |
Abiraterone acetate |
Large oncology franchise before generic entry |
Compound and formulation protection historically important |
| Xtandi |
Enzalutamide |
High-value androgen-receptor inhibitor |
More recent patent estate and substantial revenue exposure |
| Erleada |
Apalutamide |
Earlier-stage prostate-cancer use |
Newer branded exclusivity |
| Nubeqa |
Darolutamide |
Growing androgen-receptor inhibitor |
Newer patent and regulatory protection |
Casodex’s main residual advantage is cost. Its disadvantages are lower differentiation, less attractive modern treatment positioning, and weaker protection against therapeutic substitution.
What FDA regulatory status does Casodex have?
The FDA approved Casodex as a prescription drug for use with an LHRH analog in metastatic prostate carcinoma. Generic bicalutamide products are approved through the ANDA process and must demonstrate pharmaceutical equivalence and bioequivalence to the reference product. [1][6]
Bicalutamide is not a biologic. Biosimilar regulation under the Public Health Service Act does not apply. The relevant competition is conventional generic competition under the Federal Food, Drug, and Cosmetic Act.
The FDA label includes clinically important warnings, including liver effects and risks associated with combination androgen-deprivation therapy. These warnings apply to bicalutamide products generally through their approved labeling. [1]
What litigation and settlement agreements affect Casodex?
Casodex has no current litigation profile comparable with a recently launched oncology product facing active ANDA challenges. The important legal period was the pre-generic transition, when patent certifications, potential Paragraph IV litigation, and launch timing affected AstraZeneca’s remaining branded revenue.
Any historical settlement would have mattered primarily through the agreed generic-entry date, but the long-term market outcome was unchanged: bicalutamide became broadly available from generic suppliers.
The absence of a material current litigation barrier reduces the asset’s value for licensing or acquisition. A buyer would acquire a mature generic molecule or a declining brand, not a defensible specialty pharmaceutical franchise.
What licensing deals shaped the Casodex market?
Casodex originated from research conducted by Imperial Chemical Industries, whose pharmaceutical operations later became part of Zeneca and then AstraZeneca. The principal strategic transaction was corporate consolidation rather than a recent product-specific licensing deal.
No current high-value licensing structure materially supports Casodex revenue. The product’s commercial life is governed by generic availability, distributor relationships, regional registrations, and local pricing rather than exclusive licensing rights.
What is Casodex’s financial trajectory?
Casodex’s financial path has four stages.
1. Launch and adoption: 1995 through the late 1990s
Sales grew as clinicians adopted bicalutamide as an oral antiandrogen used with LHRH therapy. AstraZeneca benefited from branded pricing and limited direct competition.
2. Peak franchise period: early to mid-2000s
Annual global sales reached roughly the billion-dollar range during the product’s mature branded period, according to AstraZeneca reporting. Casodex was a significant contributor to the company’s oncology and urology portfolio. [2][3]
3. Patent expiry and generic erosion: late 2000s through early 2010s
Generic approvals reduced prices and displaced branded prescriptions. Revenue declined through both lower volume and lower realized price. AstraZeneca’s reporting increasingly reflected the loss of exclusivity and the aging profile of the product.
4. Mature generic market: 2010s through the 2020s
Branded Casodex became economically secondary. Generic bicalutamide continued to generate unit sales, but the value accrued mainly to generic manufacturers and wholesalers. AstraZeneca’s financial exposure shifted toward newer oncology products, including more commercially protected therapies.
| Financial phase |
Revenue pattern |
Primary driver |
| Launch |
Rising |
Clinical adoption |
| Mature brand |
Approximately billion-dollar global franchise |
Broad use and branded pricing |
| Generic entry |
Rapid decline |
Price and prescription substitution |
| Mature generic |
Low-margin, fragmented |
Commodity competition |
What geographic markets still matter for bicalutamide?
The United States is a mature generic market. Europe, Japan, Canada, Latin America, and Asian markets also have generic bicalutamide, although brand persistence and reimbursement structures differ by country.
Geographic value depends on:
- Local patent expiry dates.
- National generic-substitution rules.
- Public reimbursement pricing.
- Brand loyalty.
- Availability of newer prostate-cancer therapies.
- Regulatory requirements for local manufacturing or registration.
In lower-income markets, bicalutamide can retain clinical relevance because its price is materially below newer androgen-receptor inhibitors. In high-income markets, newer drugs and treatment guidelines exert greater substitution pressure.
What manufacturing and intellectual-property barriers remain?
Manufacturing barriers are modest. Bicalutamide is a small-molecule active ingredient formulated as an oral tablet. The main operational requirements are API quality, impurity control, tablet uniformity, dissolution performance, regulatory compliance, and reliable supply.
The absence of a complex biologic process, injector, device, or sterile manufacturing requirement lowers entry costs. This supports a multi-supplier market and limits long-term pricing power.
Residual intellectual-property value may exist in specific countries, trademarks, regulatory registrations, or manufacturing know-how, but these factors do not recreate the historical Casodex monopoly.
What generic launch scenarios are most likely?
The base case is continued generic supply with low pricing and gradual clinical decline.
| Scenario |
Market outcome |
Probability profile |
| Base case |
Stable generic supply and declining clinical use |
Most likely |
| Supply disruption |
Temporary price increases or regional shortages |
Possible |
| Brand revival |
Limited unless a new indication or formulation emerges |
Unlikely |
| New patent barrier |
No credible broad barrier identified |
Unlikely |
| Therapeutic displacement |
Continued migration to newer agents |
Ongoing |
A short-term supply disruption could improve generic pricing, but it would not materially restore AstraZeneca’s historical revenue position. Any commercial revival would require new clinical data, a differentiated formulation, or a new regulatory indication.
Key Takeaways
- Casodex is AstraZeneca’s branded bicalutamide product for prostate cancer.
- The product reached approximately billion-dollar annual global sales during its mature branded period.
- Its principal compound protection expired, and generic bicalutamide entered the market during the late 2000s and early 2010s.
- The current patent estate is commercially weak, with no meaningful formulation or device barrier.
- Paragraph IV litigation is historical rather than a material current market issue.
- Generic competition has caused major price and revenue erosion.
- Newer agents, including enzalutamide, apalutamide, darolutamide, and abiraterone, have displaced Casodex in higher-value treatment segments.
- Casodex has no biosimilar risk because bicalutamide is a small molecule.
- Residual value is concentrated in low-cost generic supply and selected international markets.
- The product is unsuitable as a conventional branded-growth asset without a new indication, formulation, or commercial repositioning.
FAQs
Is Casodex still sold in the United States?
Generic bicalutamide is widely available in the United States. Branded Casodex has little commercial importance compared with the generic products.
Is bicalutamide the same as Casodex?
Yes. Casodex is the original brand name, while bicalutamide is the active ingredient and the name used by generic manufacturers.
Can bicalutamide still be used with Lupron?
Yes. Bicalutamide is approved for use with an LHRH analog, including therapies in the Lupron class, for the labeled metastatic prostate-cancer indication.
Does Casodex have orphan-drug exclusivity?
Casodex’s commercial protection did not depend on a current orphan-drug exclusivity period. Its principal market protection came from historical patent and branded regulatory rights.
Why did Casodex lose market share to Xtandi?
Xtandi, or enzalutamide, has a newer mechanism and stronger modern clinical positioning in advanced prostate cancer. It also entered with active patent protection and branded pricing, while bicalutamide became a low-cost generic.
References
- U.S. Food and Drug Administration. (2011). Casodex (bicalutamide) prescribing information.
- AstraZeneca PLC. (2003). Annual report and Form 20-F.
- AstraZeneca PLC. (2009). Annual report and Form 20-F.
- U.S. Patent and Trademark Office. (1987). U.S. Patent No. 4,636,505: Antiandrogenic compounds.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, commonly known as the Orange Book.
- U.S. Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drugs database.
